| 2026-08-13 | 8-K | Form 8-K, Item 7.01 |
| 2026-08-12 | Deck | PTC Therapeutics Fabry Disease Transaction Call FLS |
| 2026-08-12 | Press release | PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program |
| 2026-07-30 | Deck | PTC Corporate Presentation – July 2026 |
| 2026-07-30 | Press release | PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-16 | Press release | PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday |
| 2026-06-18 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-17 | Press release | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-16 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-15 | Press release | PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes |
| 2026-06-15 | Press release | PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes |
| 2026-06-09 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-05 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-07 | Deck | PTC Conference Call to Report First Quarter 2026 Financial Results |
| 2026-05-07 | Press release | PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | PTC Therapeutics to Participate in Upcoming Investor Conferences |
| 2026-04-28 | Press release | PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam |
| 2026-04-28 | Press release | PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study |
| 2026-04-28 | 8-K | Form 8-K, Item 7.01 |
| 2026-04-22 | Press release | PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026 |
| 2026-04-20 | Proxy | Definitive proxy statement |
| 2026-04-17 | Press release | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-25 | Press release | PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors |
| 2026-03-25 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-13 | Press release | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-23 | Press release | PTC Therapeutics to Participate at Upcoming Investor Conferences |
| 2026-02-20 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-19 | Press release | PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-12 | Press release | PTC Therapeutics Provides Regulatory Update on Translarna™ |
| 2026-02-12 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-05 | Press release | PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday |
| 2026-01-12 | Press release | PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference · 2025 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |